Scientific, political pressures colliding at FDA, delaying rare disease treatment for patients who have few or no options, experts said at CNBC Cures Summit.
The FDA proposed new guidelines for approving experimental therapies for rare diseases without large group studies.
Here’s how drug developers can best approach interactions with the agency following last year’s seismic changes to its leadership, workforce and policies.
A Senate hearing probed whether the Food and Drug Administration's process for approving rare-disease therapies is ...
In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for ...
A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...
In a major shift, the US Food and Drug Administration is relaxing a long-standing drug approval requirement for common diseases.
When the US Food and Drug Administration (FDA) approved benzgalantamine (Zunveyl) in July 2024 for Alzheimer’s disease, it was hailed by its manufacturer as a ‘major breakthrough’.1 In reality, ...
Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...
Federal health officials yesterday issued a proposal that would make it easier for patients with rare diseases to receive treatment.
Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the ...
The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results